Supportive secondary endpoints were semaglutide plasma concentration 24 h after last dose at SS ( C tau, 24h,SS ) and time to maximum semaglutide plasma concentration at SS ( t max, 024h,SS )
When applied topically at concentrations of 1 to 3%, GHK-Cu significantly improves skin firmness, thickness and elasticity after 8 to 12 weeks
Currently, an ongoing phase III, multicenter, randomized, sham-controlled, double-blind trial is evaluating AT-04s efficacy and safety for endometriosis-related pain (dysmenorrhea, dyspareunia, chronic pelvic pain), with the primary outcome being the change in Numeric Rating Scale score at 16 weeks (36)
Cesari, M., Marzetti, E
The findings highlighted promising trends in behaviors, costs, and health outcomes.
Recommendations depend on medical history, symptoms, labs, medications, and safety considerations